TABLE 1.
Imaging Response Guidelines for Hepatocellular Carcinoma
| System | Classification | Definition |
|---|---|---|
| World Health Organization (WHO) Guidelines | CR | 100% decrease in cross-product of target lesion(s) |
| PR | ≥ 50% decrease in cross-product of target lesion(s) | |
| SD | <50% decrease to ≤25% increase in cross-product of target lesion(s) | |
| PD | >25% increase from maximum response of target lesion(s) | |
| Response Evaluation Criteria for Solid Tumors (RECIST) Guidelines | CR | 100% decrease in maximum diameter of target lesion(s) |
| PR | ≥30% decrease in maximum diameter of target lesion (s) | |
| SD | <30% decrease to ≤20% increase in maximum diameter of target lesion(s) | |
| PD | >20% increase from maximum response of target lesion(s) | |
| European Association for Study of the Liver (EASL) Guidelines* | CR | 100% decrease in amount of enhancing tissue in target lesion(s) |
| PR | ≥50% decrease in amount of enhancing tissue in target lesion(s) | |
| SD | <50% decrease in amount of enhancing tissue in target lesion(s) | |
| PD | >25% increase in amount of enhancing tissue in target lesion(s) and/or New enhancement in previously treated lesions warranting further LRT |
LRT=locoregional therapy, CR=Complete response, PR=Partial response, SD=Stable disease, PD=Progressive disease
*
To report EASL response conservatively, the presence of lipiodol within the tumor was counted as enhancing tissue rather than necrosis in patients who were treated using chemoembolization and evaluated using CT (n=5)